HIGHLIGHTS
- who: Wenwen Chien and collaborators from the Department of Medicine, Samuel Oschin Comprehensive Cancer Angeles, CA, USA Knight Cancer Institute, Oregon Health and Science University, Oregon have published the research work: RESEARCH Open Access, in the Journal: (JOURNAL)
- what: The aim of this study was to identify drugs that are either FDA-approved or in clinical trials for the treatment of OCCC.
- how: The authors identified the dual mTOR/PI3K inhibitor (GDC0941) with anti-proliferative activity in OCCC cell lines Also an inhibitor of mTOR (pp242) was more potent in KD compared to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.